Hemorrhoid Master Ointment
NDC Package 72654-002-01
Package Information
Hemorrhoid Master (lidocaine, phenylephrine) ointment is adults: Apply to the affected area up to 3 times dialy. This formulation utilizes a ointment delivery system. Marketed by Ebanel Laboratories, Inc, this product is identified by NDC 72654-002 and is authorized under FDA application M017.
Identification & Billing
- RxCUI: 2673304 - lidocaine 4 % / phenylephrine HCl 0.25 % Rectal Ointment
- RxCUI: 2673304 - lidocaine 0.04 MG/MG / phenylephrine hydrochloride 0.0025 MG/MG Rectal Ointment
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Amide Local Anesthetic - [EPC] (Established Pharmacologic Class)
- Amides - [CS]
- Antiarrhythmic - [EPC] (Established Pharmacologic Class)
- Local Anesthesia - [PE] (Physiologic Effect)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 72654 - Ebanel Laboratories, Inc
- 72654-002 - Hemorrhoid Master
- 72654-002-01 - 45 g in 1 TUBE
- 72654-002 - Hemorrhoid Master
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72654-002-01 identifies a specific commercial package of 45 g in 1 tube of Hemorrhoid Master, a human over the counter drug labeled by Ebanel Laboratories, Inc. This ointment is formulated for topical use and contains lidocaine; phenylephrine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ebanel Laboratories, Inc on November 01, 2019. The current certification is valid through December 31, 2027.
How is this Ebanel Laboratories, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72654000201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.